CD70-targeting CAR-T cells(UTC Therapeutics)(CD70-targeting CAR-T cells(UTC Therapeutics)) - 药物靶点：CD70_在研适应症：淋巴瘤，实体瘤，泌尿系统肿瘤_专利_临床

概要

基本信息

药物类型

自体CAR-T

别名-

靶点

CD70

作用机制

CD70调节剂(CD70抗原调节剂)、免疫细胞毒性、T淋巴细胞替代物

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症

淋巴瘤实体瘤泌尿系统肿瘤

非在研适应症-

原研机构

上海优替济生生物医药有限公司

在研机构

上海优替济生生物医药有限公司

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)临床1/2期

特殊审评-

登录后查看时间轴

关联

3

项与 CD70-targeting CAR-T cells(UTC Therapeutics) 相关的临床试验

NCT05990621 / Recruiting临床1期IIT

A Single-arm, Open-label, Dose-escalation/Expansion, Early-phase Clinical Study of Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urological Neoplasms

This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of Anti-CD70 CAR-T cell injection in patients with CD70-positive Advanced Urologic Neoplasms.

开始日期2023-07-31

申办/合作机构

海军军医大学第一附属医院

[+1]

NCT05948033 / Recruiting临床1/2期IIT

Phase I/II Study of CD70 Targeted CAR-T Cell Treatment in CD70 Positive Relapsed/Refractory Lymphoma

In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70 antigen positive Relapsed/Refractory Lymphoma . In this clinical trial, at least 12 eligible patients in dose escalation period will be enrolled to receive 3 doses of CD70-CAR cell therapy according to the "3+3" principle. In dose expansion period, additional at most 21 eligible patients will be enrolled to receive CD70-CAR-T cell therapy at dose of recommended phase 2 dose(RP2D).

开始日期2023-07-15

申办/合作机构

中国人民解放军总医院

[+1]

NCT05947487 / Recruiting临床1/2期IIT

Phase I/II Study of CD70 Targeted CAR-T Cell Treatment in CD70 Positive Advanced/Metastatic Solid Tumors

In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70 antigen positive advanced/metastatic solid tumors . In this clinical trial, at least 12 eligible patients in dose escalation period will be enrolled to receive 3 doses of CD70-CAR cell therapy according to the "3+3" principle. In dose expansion period, additional at most 21 eligible patients will be enrolled to receive CD70-CAR-T cell therapy at dose of recommended phase 2 dose(RP2D).

开始日期2023-07-15

申办/合作机构

中国人民解放军总医院

[+1]

100 项与 CD70-targeting CAR-T cells(UTC Therapeutics) 相关的临床结果

登录后查看更多信息

100 项与 CD70-targeting CAR-T cells(UTC Therapeutics) 相关的转化医学

登录后查看更多信息

100 项与 CD70-targeting CAR-T cells(UTC Therapeutics) 相关的专利（医药）

登录后查看更多信息

1

项与 CD70-targeting CAR-T cells(UTC Therapeutics) 相关的文献（医药）

2018-03-01·Oral Oncology2区 · 医学

CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma

2区 · 医学

Article

作者: Bennett, Katie B ; Wang, Dunrui ; Chang, Lung-Ji ; Tseng, Jennifer E ; Fredenburg, Kristianna M ; Park, Yuk Pheel ; Jin, Linchun ; Huang, Jianping ; Chan, Edward K L

OBJECTIVESIn accordance with the Precision Medicine Initiative, new treatment strategies for head and neck squamous cell carcinoma (HNSCC) are needed to yield better therapeutic outcomes. The purpose of this study was to establish and validate chimeric antigen receptor (CAR)-T cells targets in HNSCC.METHODSPutative CAR-T antigens were identified in The Cancer Genome Atlas database. To validate antigen suitability, quantitative RT-PCR, flow cytometry, and immunofluorescent staining were performed. A retroviral human CD70 CAR construct, using truncated CD27 conjugated with 4-1BB and CD3-zeta costimulatory molecules, was used to transduce activated human T cells to generate CD70 CAR-T cells. Cell-based cytotoxicity and cytokine ELISAs were used to measure efficacy of killing.RESULTSNine potential CAR-T targets (CD276, EGFR, MICA, MICB, MAGE-A4, FAP, EPCAM, CD70, B4GALNT1) were identified based on their high expression in tumors compared to flanking control tissues. CD70 was selected for further proof-of-principle analysis based on its differential expression in several tumor subtypes, and showed substantial heterogeneity in individual tumors analyzed. Cell surface CD70 protein and CD70 mRNA were detected from low to high levels in established HNSCC cancer cell lines. CD70 was highly expressed in 4 of 21 tumor biopsies (19%), and 3 of 4 specimens showed strong CD70 expression on the tumor cell surface. CD70-specific CAR-T cells were generated and further demonstrated to recognize and kill CD70-positive HNSCC cells efficiently, but not CD70-negative cancer cells.CONCLUSIONCD70-specific CAR-T cells specifically recognized and efficiently eliminated CD70-positive HNSCC cells. This study provides the basis for further investigation into CD70 and other CAR-T targets.

100 项与 CD70-targeting CAR-T cells(UTC Therapeutics) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
淋巴瘤	临床2期	中国	上海优替济生生物医药有限公司	2023-07-15
实体瘤	临床2期	中国	上海优替济生生物医药有限公司	2023-07-15
泌尿系统肿瘤	临床1期	中国	上海优替济生生物医药有限公司	2023-07-31